Thursday, January 3, 2019

Is Bristol-Myers Paying Too Much for Celgene? - TheStreet.com

Is Bristol-Myers Paying Too Much for Celgene?  TheStreet.com

BMY agreed to acquire CELG for $74 billion in cash and stock....BMY.

View full coverage on Google News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)